Equities

Goldenwell Biotech Inc

GWLL:QBB

Goldenwell Biotech Inc

Actions
  • Price (USD)0.20
  • Today's Change0.00 / 0.00%
  • Shares traded2.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 28 2024 17:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.050.050.21
Total Receivables, Net--0--
Total Inventory0.170.180.20
Prepaid expenses------
Other current assets, total------
Total current assets0.230.220.41
Property, plant & equipment, net00.030.05
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0--0
Total assets0.230.250.46
LIABILITIES
Accounts payable--00.11
Accrued expenses00.030.05
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.000.000
Total current liabilities0.000.030.16
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total0.140.020
Total liabilities0.140.050.16
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1.301.300.42
Retained earnings (accumulated deficit)(1.23)(1.11)(0.13)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0
Total equity0.080.200.30
Total liabilities & shareholders' equity0.230.250.46
Total common shares outstanding999996
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.